Mode
Text Size
Log in / Sign up
Phase 4 N=180 Randomized Quadruple-blind Treatment

IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population

Abdominal Wall Hernia · Pancreatic Diseases · Bowel Disease · Gastric Disease

Enrolled (actual)
180
Serious AEs
3.9%
Results posted
Jan 2021
Primary outcome: Primary: Postoperative Pain Intensity — 33; 42 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Acetaminophen Injectable Product (Drug); Sodium Chloride 0.9%, Intravenous (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Kathirvel Subramaniam
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Postoperative Pain Intensity
33; 42
SECONDARY
Total Post-operative Narcotic Consumption
27.4; 36; 31.3; 45; 30; 37.5
SECONDARY
Time to Readiness for Discharge From Post Anesthesia Care Unit (PACU)
129.00; 152.50
SECONDARY
Time to Bowel Movement
46.30; 64.66
SECONDARY
Time to Oral Intake
12.15; 9.40
SECONDARY
Time to Ambulation
18.82; 17.38
SECONDARY
Time to Hospital Discharge
4.08; 4.94
SECONDARY
Number of Participants With Readmission to the Hospital
9; 10
SECONDARY
Patient Satisfaction
10; 10; 10; 10
SECONDARY
Intensive Care Delirium Screening Checklist (ICDSC)
0; 0
SECONDARY
Post-operative Nausea
1.13; 0.60; 0.49; 0.92; 0.71; 0.75
SECONDARY
Post-operative Emesis
12; 14; 31; 45
SECONDARY
SF-12 Health Survey
38.72; 38.07; 54.02; 52.08

Summary

Number of patients with unsatisfactory pain relief defined as average visual analog scale (VAS) more than 5 with or without requirement of IVPCA for pain relief during the first 48 hours postoperative period will be compared between the two groups and form the primary outcome for the study. Postoperative pain intensity will be measured by Visual Analog Scale (VAS) with 0- being no pain and 10-being maximum pain and the analgesic efficacy in both groups will also be evaluated by the amount of total narcotic consumption (measured with IV morphine equivalent doses of analgesics used to provide pain relief).

Eligibility Criteria

Inclusion Criteria

  • Male or Female
  • 18 years of age or older
  • patients scheduled for elective colorectal, pancreatic, and other major abdominal procedure.
  • Patient consent will be obtained preoperatively for eligible study participants.

Exclusion Criteria

  • Patients who refuse to participate in the study or part of any other enhanced recovery after surgery (ERAS) research protocol.
  • Patients with a documented allergy to acetaminophen.
  • Chronic alcoholism
  • Hypovolemia
  • Chronic malnutrition
  • Preoperative renal insufficiency (creatinine clearance less than or equal to 30ml/min) or hemodialysis
  • Patients with a history of hepatic impairment, history of hepatic impairment or active hepatic disease
  • severe chronic pain condition that required daily preoperative opioid dependence
  • Patients with pre-existing dementia and/or other neuropsychiatric conditions impeding accurate assessment of pain scores or other study measures will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03198871). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search